Horizon Therapeutics ticks higher amid report FTC meeting unrelated to Amgen deal
JHVEPhoto/iStock Editorial via Getty Images
Horizon Therapeutics (NASDAQ:HZNP) rose 1% amid a report that a Federal Trade Commission closed door meeting on Friday is likely unrelated to the Amgen's (NASDAQ:AMGN) planned acquisition.
The meeting appears to be unrelated to the transaction, according to traders, who cited a CTFN report that's circulating. The parties believe that the FTC staff has recommended clearance for the deal, though FTC Chair Lina Khan could do a "walk around" vote if she desired.
The FTC has a closed door meeting on Friday scheduled from 3pm-5pm for the consideration of two nonpublic law enforcement matters. While sometimes the meetings are about public companies, often times they are about private firms.
The report comes after a Dealreporter item a week ago said that Amgen's (AMGN) planned acquisition is expected to close on May 23. Horizon (HZNP) employees were told to expect a deal close on May 23.
Investors are awaiting a May 22 Irish court hearing for Horizon's (HZNP) planned $28 billion sale to Amgen (AMGN) as well as FTC approval for the deal. Horizon (HZNP) and Amgen (AMGN) in late January confirmed they received a second request from the FTC.
More on Horizon Therapeutics/Amgen

Amgen: Questioning The Horizon Therapeutics Acquisition
Horizon Therapeutics Q1 miss irrelevant, deal still likely to close - analyst